X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3112) 3112
humans (2985) 2985
everolimus (2882) 2882
female (1832) 1832
male (1727) 1727
sirolimus - analogs & derivatives (1669) 1669
middle aged (1428) 1428
aged (1189) 1189
sirolimus - administration & dosage (1155) 1155
treatment outcome (1141) 1141
oncology (1129) 1129
adult (763) 763
drug-eluting stents (690) 690
cardiac & cardiovascular systems (682) 682
everolimus - administration & dosage (638) 638
cancer (622) 622
sirolimus - therapeutic use (581) 581
care and treatment (539) 539
rapamycin (529) 529
time factors (528) 528
transplantation (525) 525
animals (514) 514
tor serine-threonine kinases - antagonists & inhibitors (508) 508
immunosuppressive agents - administration & dosage (492) 492
mammalian target (453) 453
sirolimus (450) 450
surgery (434) 434
immunosuppressive agents - therapeutic use (423) 423
analysis (399) 399
antineoplastic agents - therapeutic use (391) 391
sirolimus - adverse effects (389) 389
mtor (386) 386
prosthesis design (384) 384
antineoplastic combined chemotherapy protocols - therapeutic use (376) 376
prospective studies (373) 373
pharmacology & pharmacy (370) 370
risk factors (367) 367
cardiovascular agents - administration & dosage (359) 359
metastasis (348) 348
angiogenesis inhibitors (335) 335
carcinoma, renal cell - drug therapy (335) 335
medicine & public health (332) 332
efficacy (331) 331
kidney neoplasms - drug therapy (329) 329
stent (326) 326
coronary artery disease - therapy (325) 325
therapy (316) 316
follow-up studies (312) 312
sirolimus - pharmacology (310) 310
trial (306) 306
research (305) 305
sunitinib (305) 305
stents (300) 300
thrombosis (299) 299
tumors (293) 293
abridged index medicus (286) 286
coronary angiography (286) 286
clinical trials (280) 280
percutaneous coronary intervention (274) 274
immunosuppressive agents - adverse effects (269) 269
retrospective studies (269) 269
drug therapy (265) 265
disease-free survival (263) 263
chemotherapy (259) 259
aged, 80 and over (256) 256
health aspects (252) 252
everolimus - therapeutic use (249) 249
drug therapy, combination (245) 245
implantation (245) 245
everolimus - adverse effects (244) 244
patients (243) 243
absorbable implants (242) 242
immunology (240) 240
dose-response relationship, drug (236) 236
cyclosporine (228) 228
sorafenib (226) 226
antineoplastic agents - administration & dosage (225) 225
percutaneous coronary intervention - instrumentation (224) 224
kaplan-meier estimate (223) 223
breast cancer (222) 222
survival (221) 221
kidney transplantation (217) 217
interferon-alpha (215) 215
mice (215) 215
percutaneous coronary intervention - adverse effects (212) 212
safety (212) 212
cardiovascular (211) 211
temsirolimus (210) 210
tor serine-threonine kinases - metabolism (210) 210
breast neoplasms - drug therapy (208) 208
double-blind (201) 201
carcinoma, renal cell (200) 200
kidney neoplasms - pathology (199) 199
cell line, tumor (196) 196
urology & nephrology (189) 189
antineoplastic agents - adverse effects (187) 187
hematology, oncology and palliative medicine (187) 187
renal cell carcinoma (186) 186
protein kinase inhibitors - therapeutic use (183) 183
tacrolimus (182) 182
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3640) 3640
Japanese (21) 21
French (18) 18
German (16) 16
Spanish (7) 7
Russian (6) 6
Italian (4) 4
Polish (4) 4
Hungarian (2) 2
Czech (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 08/2015, Volume 126, Issue 6, pp. 721 - 732
Waldenstrom macroglobulinemia (WM) is a B-cell neoplasm manifested by the accumulation of clonal immunoglobulin (Ig)M-secreting lymphoplasmacytic cells. MYD88... 
CONSENSUS PANEL RECOMMENDATIONS | 2ND INTERNATIONAL WORKSHOP | L265P SOMATIC MUTATION | MULTIPLE-MYELOMA | RITUXIMAB THERAPY | IMMUNOGLOBULIN-M | MYD88 L265P | LYMPHOPROLIFERATIVE DISORDERS | LYMPHOPLASMACYTIC CELLS | INHIBITOR EVEROLIMUS | HEMATOLOGY | Cyclophosphamide - administration & dosage | Nitrogen Mustard Compounds - administration & dosage | Waldenstrom Macroglobulinemia - therapy | Humans | Middle Aged | Pyrazines - administration & dosage | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Transplantation, Autologous | Molecular Targeted Therapy | Waldenstrom Macroglobulinemia - pathology | Adult | Receptors, CXCR4 - genetics | B-Lymphocytes - pathology | Boronic Acids - administration & dosage | Everolimus | B-Lymphocytes - metabolism | Waldenstrom Macroglobulinemia - diagnosis | Immunoglobulin M - genetics | Gene Expression | Genetic Predisposition to Disease | Sirolimus - analogs & derivatives | Bortezomib | Pyrimidines - administration & dosage | Myeloid Differentiation Factor 88 - genetics | Antineoplastic Combined Chemotherapy Protocols | Hematopoietic Stem Cell Transplantation | Rituximab | Vidarabine - analogs & derivatives | Cladribine - administration & dosage | Plasmapheresis | Receptors, CXCR4 - metabolism | B-Lymphocytes - drug effects | Sirolimus - administration & dosage | Pyrazoles - administration & dosage | Bendamustine Hydrochloride | Aged | Oligopeptides - administration & dosage | Vidarabine - administration & dosage | Myeloid Differentiation Factor 88 - metabolism | Waldenstrom Macroglobulinemia - genetics | Index Medicus | Abridged Index Medicus
Journal Article
Current Medical Research and Opinion, ISSN 0300-7995, 04/2016, Volume 32, Issue 4, pp. 741 - 747
Journal Article
Cancer Discovery, ISSN 2159-8274, 2014, Volume 4, Issue 5, pp. 546 - 553
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 12, pp. 1202 - 1209
Journal Article
International Journal of Cancer, ISSN 0020-7136, 11/2016, Volume 139, Issue 9, pp. 2047 - 2055
Bromodomain and extraterminal (BET) bromodomain (BRD) proteins are epigenetic readers that bind to acetylated lysine residues on chromatin, acting as... 
blood brain barrier | glioblastoma | BET inhibitor | OTX015 (MK‐8628) | combination studies | Combination studies | Blood brain barrier | Glioblastoma | OTX015 (MK-8628) | SELECTIVE-INHIBITION | C-MYC | ACUTE MYELOID-LEUKEMIA | MALIGNANT GLIOMA | ONCOLOGY | RECURRENT | BROMODOMAIN INHIBITION | TARGETS | PROTEINS | SMALL-MOLECULE INHIBITION | BRD4 | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Acetanilides - administration & dosage | Heterocyclic Compounds, 3-Ring - pharmacology | Humans | Everolimus - administration & dosage | Antineoplastic Agents - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dacarbazine - pharmacology | Dacarbazine - analogs & derivatives | Camptothecin - administration & dosage | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Camptothecin - analogs & derivatives | Cell Survival - drug effects | Acetanilides - pharmacology | Dacarbazine - administration & dosage | Everolimus - pharmacology | Brain Neoplasms - drug therapy | Blood-Brain Barrier - drug effects | Drug Synergism | Xenograft Model Antitumor Assays | Animals | Heterocyclic Compounds, 3-Ring - administration & dosage | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Glioblastoma - drug therapy | Camptothecin - pharmacology | Epigenetic inheritance | Chemotherapy | Chromatin | RNA | Lysine | Analysis | Brain tumors | Gene expression | Glioblastoma multiforme | Protein binding | Cancer | Epigenetics | Cancer therapies | Brain cancer | Tumors | Index Medicus
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2017, Volume 23, Issue 2, pp. 330 - 335
Journal Article
American Journal of Transplantation, ISSN 1600-6135, 08/2014, Volume 14, Issue 8, pp. 1828 - 1838
Journal Article
Journal Article
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 09/2012, Volume 434, Issue 1-2, pp. 306 - 314
Journal Article
Annals of Oncology, ISSN 0923-7534, 08/2016, Volume 27, Issue 8, pp. 1579 - 1585
The combination of the campothecan-containing nanoparticle-drug conjugate, CRLX101 and bevacizumab is well tolerated, safe, and active in a heavily pretreated... 
Hypoxia-inducible factor | Angiogenesis | CRLX101 | Recommended phase II dose | Nanoparticle-drug conjugate | Renal cell carcinoma | renal cell carcinoma | nanoparticle-drug conjugate | EVEROLIMUS | ONCOLOGY | HYPOXIA-INDUCIBLE FACTOR-1-ALPHA | angiogenesis | recommended phase II dose | TOPOTECAN | hypoxia-inducible factor | CANCER | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Cyclodextrins - adverse effects | Nanoparticles - chemistry | Antineoplastic Combined Chemotherapy Protocols - chemistry | Bevacizumab - adverse effects | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Drug-Related Side Effects and Adverse Reactions - pathology | Angiogenesis Inhibitors - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Adult | Camptothecin - administration & dosage | Female | Carcinoma, Renal Cell - drug therapy | Angiogenesis Inhibitors - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Bevacizumab - administration & dosage | Carcinoma, Renal Cell - pathology | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Cyclodextrins - administration & dosage | Aged | Nanoparticles - administration & dosage | Drug-Related Side Effects and Adverse Reactions - classification | Index Medicus | nanoparticle–drug conjugate | Original
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2009, Volume 27, Issue 16, pp. 2630 - 2637
Purpose Cross-talk between the estrogen receptor (ER) and the phosphoinositide-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathways is a mechanism... 
INHIBITOR RAD001 EVEROLIMUS | MAMMALIAN TARGET | ADVANCED SOLID TUMORS | ONCOLOGY | TAMOXIFEN | DOUBLE-BLIND | ENDOCRINE THERAPY | AKT | POSTMENOPAUSAL WOMEN | PROGNOSTIC VALUE | MTOR | Cyclin D1 - metabolism | Palpation | Triazoles - administration & dosage | Phosphorylation | Receptors, Estrogen - metabolism | Ribosomal Protein S6 Kinases - metabolism | United States | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Ki-67 Antigen - metabolism | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Nitriles - administration & dosage | Time Factors | Aged, 80 and over | Biomarkers, Tumor - metabolism | Postmenopause | Adult | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Everolimus | Aromatase Inhibitors - administration & dosage | Sirolimus - analogs & derivatives | Double-Blind Method | Europe | Treatment Outcome | Breast Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Gene Expression Regulation, Enzymologic | Phosphatidylinositol 3-Kinases - genetics | Sirolimus - administration & dosage | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Biopsy | Breast Neoplasms - pathology | Aged | Cell Proliferation - drug effects | Mutation | Index Medicus
Journal Article